Organogenesis (NASDAQ:ORGO) Stock Price Down 2.1% – What’s Next?

Organogenesis Holdings Inc. (NASDAQ:ORGO) shares traded down 2.1% during mid-day trading on Friday . The company traded as low as $5.10 and last traded at $5.14. 220,836 shares were traded during mid-day trading, a decline of 79% from the average session volume of 1,071,226 shares. The stock had previously closed at $5.25.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upped their price target on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th.

Organogenesis Stock Down 4.6 %

The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $635.41 million, a PE ratio of -83.50 and a beta of 1.66. The business’s 50 day simple moving average is $3.85 and its 200 day simple moving average is $3.43.

Insider Buying and Selling at Organogenesis

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the transaction, the director now owns 166,879 shares in the company, valued at approximately $851,082.90. This represents a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 36.90% of the company’s stock.

Hedge Funds Weigh In On Organogenesis

A number of hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in Organogenesis during the 4th quarter worth $38,000. Captrust Financial Advisors acquired a new position in shares of Organogenesis during the third quarter valued at about $36,000. Intech Investment Management LLC acquired a new position in shares of Organogenesis during the third quarter valued at about $43,000. Palumbo Wealth Management LLC bought a new stake in Organogenesis in the fourth quarter valued at about $65,000. Finally, ProShare Advisors LLC increased its stake in Organogenesis by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 20,329 shares of the company’s stock valued at $65,000 after acquiring an additional 6,689 shares during the period. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.